Lilly exercises its rights to potential cancer treatments outside China, while Innovent will now have rights to those potential treatments inside China
Lilly and Innovent Biologics Expand Their Strategic Alliance to Include Immuno-Oncology Bispecific Antibodies in China and Globally (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.